Ten years together.

MYELOMA PATIENTS EUROPE (MPE)

2021: YEAR IN REVIEW

Empowering myeloma advocacy across Europe
INDEX

- Message from the Board President and CEO...3
- Myeloma Patients Europe (MPE)..........................5
  - MPE Strategic Objectives..................................5
  - MPE Membership..............................................6
  - MPE Board......................................................9
  - MPE Staff........................................................10
- 2021 MPE Programme Highlights.........................11
  - Access and Policy.............................................12
  - Medical Education and Scientific Engagement........14
  - Patient Evidence.............................................16
  - Capacity Building and Advocacy.........................17
  - COVID-19 Workstream.......................................20
  - European Commission Projects..........................21
- MPE 10th Anniversary.......................................23
- MPE 2021 Funders.............................................24
MESSAGE FROM THE BOARD PRESIDENT AND CEO

Dear friends, colleagues and supporters,

This year marks MPE’s 10th anniversary: 10 years advocating, 10 years empowering and 10 years working together to improve the lives of myeloma and AL amyloidosis patients across Europe. Whilst MPE has seen many changes in its 10-year history, one thing has not changed in the past decade – our commitment to our mission: to provide education, information and support to member groups, and to advocate at European, national and local levels for the best possible research and equal access to treatment and care.

As we reflect on the past year, we want to extend a heartfelt thank you to our inspiring members, generous sponsors and dedicated stakeholders. There are many accomplishments to celebrate from 2021, none of which would have been possible without your support. We share these achievements with each of you.

This year, MPE launched two projects that will provide distinct and indispensable resources for the patient community: the launch of the redesigned Myeloma Access Atlas, helping the patient community to advocate more effectively for equal access to medicines, and the development of the European Myeloma Clinical Trial Navigator, which will significantly improve patients’ ability to make informed decisions about participation in clinical trials. These two projects usher in a new era of data-driven advocacy, true collaboration among multiple stakeholders to support patient organisations and the increase of transparency to empower individual patients.
2021 also saw the expansion of our Evidence Generation Unit and the launch of a new model to facilitate collaboration between MPE, academia, industry and regulators. Through several key research projects, MPE and our partners will better understand the complex and diverse needs of patients and carers, and leverage the findings to identify solutions to address the issues of highest concern for MPE members and the broader patient community.

MPE’s core programmes, including our Advocate Development Programme, annual Masterclass, Scholarship and Capacity Building Programme and more, continue to build and galvanise a network of skillful, effective and resilient myeloma patient advocacy organisations and individual advocates across Europe. These programmes remain deeply attuned to the evolving needs of the patient community and our member organisations, providing support and resources for evidence-based advocacy at local, national and European levels.

Our ongoing involvement in two Horizon 2020 projects and two Innovative Medicines Initiative (IMI) projects this year has strengthened MPE’s position and partnerships with key stakeholders and institutions across Europe. MPE is proud to collaborate through these consortia, the efforts of which will have lasting and profound impacts on the quality and delivery of patient treatment and care.

In this report you will read about MPE’s major successes in 2021 and our plans to continue to improve patient outcomes across Europe, as well as support our members who help thousands of patients and carers access the information, support and treatment they need everyday.

We remain grateful for your partnership and support, which will help to ensure our strength and impact for the next 10 years and beyond.

ANANDA PLATE  
CEO of Myeloma Patients Europe (MPE)

HANS SCHEURER  
President of Myeloma Patients Europe (MPE)
**MYELOMA PATIENTS EUROPE (MPE)**

Myeloma Patients Europe (MPE) is an umbrella organisation of myeloma and AL amyloidosis patient groups across Europe. The mission of the organisation is to provide education, information and support to member groups, and to advocate at European, national, and local levels for the best possible research and equal access to treatment and care. To achieve its aims, MPE works directly with members, healthcare professionals, reimbursement authorities, regulators, politicians, pharmaceutical companies and the media to ensure all stakeholders are collaborating to improve patient outcomes and reduce inequalities in Europe.

**MPE’s Strategic Objectives**

In 2019, MPE’s board and membership developed and confirmed seven strategic objectives to guide our work programme through 2024. All of the activities of MPE support one or more of the following:

- Provide a strong voice for myeloma patients at a European and international level
- Strengthen members’ and individual advocates’ ability to advocate effectively
- Secure a larger patient voice in myeloma research
- Accelerate progress in the treatment and care of myeloma patients
- Increase the number of patients who have their myeloma diagnosed in a timely manner
- Improve access to optimal treatment and care for all myeloma patients in Europe
- Strengthen MPE’s effectiveness, sustainability and capacity to take collective action
MPE MEMBERSHIP

In 2021, MPE had 49 full and associate members representing 31 different countries. MPE continues to grow and support its membership to create a network of highly efficient, effective and sustainable myeloma patient organisations across Europe.
**Full Members**

**Armenia**
- Armenian Hematology Association

**Austria**
- Multiples Myelom Selbsthilfe Österreich (MMSOE)
- Myelom- und Lymphomhilfe Österreich

**Belgium**
- Contactgroep Myeloom en Waldenström Patiënten Vlaanderen vzw (CMP vzw)
- MyMu Wallonie-Bruxelles (MyMu)

**Croatia**
- Udruga za podršku oboljelima od multiplog mijeloma (Mijelom CRO)
- Hrvatska udruga leukemija i limfomi (HULL)

**Denmark**
- Dansk Myelomatose Forening

**Finland**
- Suomen Syöpäpotilaat – Cancerpatienterna i Finland ry

**France**
- Association Française des Malades du Myélome Multiple (AF5M)

**Germany**
- AMM-Online
- Deutsche Leukämie- & Lymphom-Hilfe e.V. (DLH)
- Myelom-Gruppe RHEIN-MAIN – Leukaemiehilfe RHEIN-MAIN e.V. (LHRM)
- Myelom Deutschland e.V.

**Iceland**
- Perluvinir

**Ireland**
- Multiple Myeloma Ireland

**Israel**
- AMEN Israel
- Amyloidosis Israel

**Latvia**
- Onkologisko pacientu atbalsta biedriba “Dzivibas koks”

**Lithuania**
- Asociacija “Kraujas”

**Macedonia**
- BORKA
- HEMA

**Malta**
- Myeloma, Leukemia and Lymphoma Malta

**Netherlands**
- Stichting Hematon
- Stichting Amyloïdose Nederland (SAN)

**Norway**
- Blodkreft Foreningen

**Poland**
- Fundacja Carita – Żyć ze Szpiczakiem
- Polskie Stowarzyszenie Pomocy Chorym na Szpiczaka

**Portugal**
- Associação Portuguesa Contra a Leucemia (APCL)
- Associação Portuguesa Leucemias e Linfomas (APLL)

**Romania**
- Myeloma Euronet Romania (MER)
- SOS Mielom
Associate Members

**Czech Republic**
- Klub pacientů mnohočetný myelom, z.s.

**Bosnia and Herzegovina**
- Bosnian Myeloma Patient Group

**Portugal**
- Centro de Histocompatibilidade do Norte (CHN)

---

MPE extends a special thank you to our members and the myeloma patient community. You inspire us with the work you do every day and we could not have achieved so much this year without your support and partnership.
MPE BOARD

The MPE Board is multidisciplinary and responsible for the strategy, governance and accountability of the organisation. The Board is comprised of myeloma patients, caregivers and advocates, who are supported by MPE staff as well as by an expert Medical Advisory Committee.

MPE’s 2021 Board Members

Hans Scheurer
President

Ron Dloomy
Vice President

Johannes Brenner
Treasurer

Riikka-Leena Manninen
Secretary

Kristina Modic
Board Member

Biljana Dodeva-Biba
Board Member

Roman Slomkowski
Board Member

Lise-Lott Eriksson
Board Member

Nikita E. Shklovskiy-Kordi
Board Member
MPE expanded its staff in 2021 to increase capacity in each workstream and introduce new programmes to meet the evolving needs of our members and the patient community. Now, with offices in Germany, the UK, Spain and Belgium, MPE has grown to become an international team of dedicated professionals.
2021 MPE PROGRAMME HIGHLIGHTS

With the leadership of our board, the dedication of our staff and support of our stakeholders, MPE has reached incredible milestones this year. The following pages provide a summary of the major accomplishments from each workstream.
To ensure all patients have access to the best treatment and care, and to represent their interests at the European level.

**MPE’s Access and Policy workstream** provides members with the tools and resources to advocate effectively for improved access to timely diagnosis, treatment and care. Through this workstream MPE also works closely with regulators, reimbursement / HTA stakeholders, patient organisations and policymakers to influence decisions and initiatives that address and reduce access inequalities in Europe.

In 2021, MPE launched our redesigned **Myeloma Access Atlas**, an online platform providing myeloma and AL amyloidosis patient organisations with the information and tools needed to work effectively on access issues. The Atlas provides country-specific and comparative information on European healthcare systems, including data on system performance and on access inequalities to myeloma drugs and drugs combinations. The aim behind the data and tools provided is to identify, understand and overcome variation in access to treatment and care in Europe, and empower advocates to create their own strategic advocacy plan or to seek support from MPE as required.

Over the past year, MPE has increased its engagement in **Health Technology Assessment International (HTAi)**, a collaboration of global stakeholders involved in HTA, working with key stakeholders to develop and implement an international template to support patient submissions in health technology assessments (known as the International Summary of Information for Patients template). MPE is also represented on the HTAi Patient and Citizens Interest Group (PCIG), which guides the strategic direction of HTAi and develops projects on patient and citizen involvement. Through this consortium, MPE and our colleagues are working to enable more meaningful patient involvement in the HTA process.

On the European access side, MPE participated in **two EMA assessments of new medicines**, ensuring that patients’ needs and preferences were considered in the decision-making process. On a national level, through the Atlas Coaching Programme, MPE supported the Carita Foundation, one of our members in Poland, to petition the Polish Health Ministry to support the reinstatement of myeloma drugs for national funding. The data available in the Myeloma Access Atlas helped support their case and through collaborative action, Carita and MPE were able to improve access for Polish myeloma patients.
Finally, MPE has expanded its work with **Europe’s Beating Cancer Plan**. In collaboration with the Workgroup of European Cancer Patient Advocacy Networks (WECAN), MPE has influenced the development of the Cancer Plan and the report of the Special Committee on Beating Cancer (BECA) within the European Parliament, to ensure they represent the aligned opinion of the patient advocacy community and the needs of European cancer patients and their families.

**MYELOMA ACCESS ATLAS**

**Atlas Coaching Programme** to develop tailored strategies to overcome national access challenges - **9 steps for your MPE advocacy roadmap!**

3,735 page views and 862 users in its first month

**Country-specific** and comparative information on European healthcare systems

[www.mpeurope.org/atlas](http://www.mpeurope.org/atlas)
This year, MPE achieved a long-term goal of developing a European Myeloma Clinical Trial Navigator. With the support of our partners, MPE launched phase I of building an online search tool to help patients and advocates find clinical trials in Europe for multiple myeloma, MGUS, smouldering myeloma and AL amyloidosis. MPE’s Navigator will be a patient-friendly tool that allows searches in multiple languages as well as finding general information on clinical trials, enrolment and cross-border access. Phase I focused on gathering evidence from patients, healthcare professionals and stakeholders to best understand how to design a platform that is clear, accessible and sustainable as well as answers the key questions from patients regarding clinical trial access at European and national levels. Design of the Navigator is underway and the platform will be launched in 2022.

While AL amyloidosis is not a cancer, the disease pathophysiology and formation are very similar to that of myeloma. Therefore, there is a clear need for collaboration between the AL amyloidosis and myeloma communities. MPE created the AL Amyloidosis workstream to support patients and their families, as well as identify opportunities to collaborate with organisations active in AL amyloidosis, and fill gaps where no resources currently exist. To this end, in 2021, MPE created new AL amyloidosis educational materials, including an animated video and infographics. MPE also developed an AL amyloidosis research protocol in advance of a 2022 research project, which will investigate the disease burden on the quality of life in AL amyloidosis patients and patient perspectives on diagnosis, as well as examine currently available and upcoming treatment options.

Lastly, to ensure MPE is working closely with healthcare providers to gather the clinical perspective on the unmet needs of the patient community and collaborate to address common challenges, MPE created our Medical Advisory Committee to provide evidence-based recommendations to our team and members in support of advocacy initiatives. Comprised of key opinion leaders representing myeloma and AL amyloidosis specialities, as well as MPE’s member countries, the Committee meets regularly to discuss the latest updates in myeloma and AL amyloidosis disease, diagnostics and treatments, and highlight issues of priority and concern. Committee members also take an active role in educating the patient community and MPE members by hosting webinars, reviewing educational materials, answering clinical questions, disseminating and participating in surveys, collaborating on research projects and joining discussion groups on selected topics.
Accessing up-to-date, patient-facing and accurate information on clinical trials can be burdensome for patients. MPE conducted individual interviews with five patients living in France, Germany, the Netherlands and the UK.

One patient brought feedback from their myeloma support group consisting of nine patients and carers. MPE obtained additional feedback from representatives from Israel, Ireland, Denmark, Poland, Lebanon, Austria and the UK.

16 online clinical trial (global and national) search tools were analysed. None of them combine all of MPE’s selection criteria and patients would need to use several or all of them to obtain the information they are looking for.

In 2021, after gathering the perspectives of patients, patient representatives and industry partners, the design of the European Myeloma Clinical Trial Navigator commenced. The Navigator will be launched in 2022, enabling patients to make informed decisions about clinical trial participation and patient organisations to advocate for better access to clinical trials in their country and at the European level.
The MPE Evidence Generation Unit (EGU) generates data to support decision-making in myeloma and AL amyloidosis. Through collaborations with stakeholders, such as academic institutions, regulatory authorities and pharmaceutical companies, MPE conducts research which will be used in future policy discussions and briefings to advocate for better and fairer myeloma care and treatment for patients.

As part of the EGU’s ongoing work to advocate and support better collection of patient reported outcome (PRO) data, the patient evidence team is a research partner on a number of quality of life research projects conducted by the EORTC (European Organisation for Research and Treatment of Cancer). MPE is supporting projects such as the development of a tool measuring financial toxicity and a guidance document which aims to develop interpretation guidelines for EORTC PRO questionnaires. These partnerships will help not only the myeloma patient community, but also the broader cancer community, to better understand the impact of treatment on patients and carers in all facets of life.

In 2021, the EGU developed a new collaborative model, which places myeloma patients (represented by MPE) at the centre of research and research decision-making. This model brings together funding and insights from our industry partners, and the expertise and credibility of academic centres, to conduct large research projects that answer the most pressing questions regarding patients’ needs. MPE acts as the research lead, coordinating the research and ensuring that patients guide and support the projects. This model will launch with two flagship projects in 2022 focused on shared decision-making and the unmet needs of working age myeloma patients.
CAPACITY BUILDING AND ADVOCACY

To build and empower a network of effective patient advocates and organisations across Europe, and to provide a strong platform for the voice of myeloma and AL amyloidosis patients to be heard.

MPE’s Capacity Building and Advocacy workstream comprises six distinct programmes designed to educate, train and galvanise patient advocates and patient organisations, as well as ensure meaningful patient involvement with stakeholders at local, national, and European levels.

Through our Scholarship and Capacity Building Programme, MPE provided scholarships for 10 member organisations to implement or expand programmes to meet the specific needs of their patient communities. Programmes ranged from 24-hour patient support helplines, to publishing information on patients’ rights, to arranging safe transportation for patients to access medical care during COVID-19. In addition to scholarships, MPE provided capacity-building support for each organisation to ensure activities were implemented effectively. Through this Programme, MPE and our members have helped hundreds of patients access the support, information and care they need.

MPE’s Advocate Development Programme (ADP), a 12-month training programme for patient advocates, had its largest and most diverse cohort to date, with eight participants ranging from individual patients seeking to start their own organisation to leaders of established organisations aiming to expand their activities. This year launched the ADP’s alumni network, which will provide ongoing counselling for participants beyond their programme year to assist them in putting their knowledge into practice and achieving their long-term advocacy goals.

The annual Masterclass brings together MPE’s members and stakeholders for scientific, advocacy, and capacity-building training sessions led by leading experts from across Europe. The 2021 Masterclass was held online to ensure the safety of participants during the COVID-19 pandemic and featured sessions on myeloma and AL amyloidosis treatment updates, access challenges in central and eastern European countries, palliative care and member organisations’ responses to COVID-19. The live event had 138 delegates from 32 countries, and the recording of each session remains available on the MPE website as an ongoing resource for members and the broader patient community. MPE’s board, leadership and members look forward to returning to an in-person Masterclass and exchanging ideas, tackling challenges and learning together in 2022.
The Myeloma-Community Advisory Board (CAB) met with key industry partners and stakeholders this year to discuss issues of priority for the patient community, including patient involvement in the drug development process, access challenges in Europe, unmet needs among patient populations and gaps in evidence. Each meeting resulted in specific action items to carry forward in the year(s) ahead to measure impact and improve outcomes for patients. In 2021, MPE launched the Myeloma Community Taskforce, a standing group of expert patients, to support the CAB in its efforts to ensure strong patient involvement in the drug development, research, and regulatory processes and decision-making.

MPE’s Information and Educational Resources initiative provides members, advocates and the patient community with the latest information on treatment and care, as well as capacity-building resources to support advocacy efforts. In 2021, in addition to conference reports, drug factsheets and Q&As, MPE also developed and published animated videos on AL amyloidosis and CAR-T, to educate patients in a dynamic way. In the autumn of 2021, MPE conducted interviews with each member to gain an in-depth understanding of members’ educational and training needs. Using these insights and results, MPE has developed a 2022 workplan that includes resources in five key areas (Access, Clinical, Evidence, Advocacy and Organisational Support) and delivered in a variety of formats, such as webinars, reports, infographics, toolkits and more, to engage and educate our members and the patient community.

Join MPE's Telegram Channel!

Discover the latest myeloma and AL amyloidosis news, plus MPE activities, on your mobile phone!

Click here to join
On 27 September 2021, MPE launched its **Year of Action on Diagnosis**, designed to raise awareness, gather real-world insights and implement a range of activities to promote the timely diagnosis of myeloma and AL amyloidosis in Europe.

Recognising that early diagnosis significantly improves the outcomes and quality of life of patients and their experience of healthcare, the Year of Action has developed and published **16 infographics in 26 different** languages on myeloma, AL amyloidosis, diagnosis challenges and disease symptoms.

In 2022, MPE will conduct surveys and focus groups with patients, carers and healthcare professionals to better understand the diagnosis challenges. The Year of Action will culminate in the first-ever **European Myeloma Day** during blood cancer awareness month in September 2022.
COVID-19 WORKSTREAM

To provide the patient community with the latest information regarding COVID-19 and its effects on myeloma and AL amyloidosis patients, and help member organisations remain robust and resilient during this pandemic.

With the support of our industry partners, MPE launched the COVID-19 workstream in 2020 to respond to the immediate needs of our member organisations and the patient communities they support. In March 2021, MPE developed infographics and a Q&A on COVID-19 vaccines, publishing these resources in 12 member languages. We also hosted a webinar, “COVID-19 Vaccines for Myeloma Patients: What You Need to Know” to inform patients and answer their questions and concerns.

In April 2021, MPE set out to gather evidence to better understand the impact of the pandemic on patients and member organisations. To this end, MPE conducted four focus groups with 17 patients and carers, resulting in the publication “The impact of the COVID-19 pandemic on the healthcare and lives of people with myeloma or AL amyloidosis and their caregivers”. Based on this report, MPE also presented a poster of our research findings at the 18th International Myeloma Workshop in September 2021 entitled “The Impact of SARS-CoV-2 (COVID-19) on the treatment and care of patients with myeloma and AL amyloidosis”.

MPE also conducted a member needs assessment with all MPE members to understand organisational needs and provide appropriate support during the pandemic. The findings were published in the report “Assessment of the needs of patient organisations during the COVID-19 pandemic” and informed the ongoing activities for the workstream, including translated materials and scholarships to support programme adaptations.

As we enter 2022 and the pandemic continues, MPE will publish an updated Q&A and factsheet on vaccines, treatment and the importance of maintaining safety precautions among patients and carers. We will also continue to share data with our members and the patient community on COVID-19’s impact on the diagnosis and treatment of myeloma to help inform ongoing advocacy strategies and patient support activities.

17 Patients and carers participated in 4 focus groups on COVID-19

35 Patient organisations interviewed to assess MPE members’ needs

15 Video interviews filmed with myeloma experts on COVID-19 and myeloma
EUROPEAN COMMISSION PROJECTS

To provide a strong voice for myeloma and AL amyloidosis patients at European and international levels, and collaborate with key stakeholders to take collective action on behalf of the patient community.

MPE remains involved in several European projects, ensuring that the voice of the myeloma and AL amyloidosis patient community is adequately reflected within the programme of work, and that resources and deliverables are designed with patients’ needs in mind.

This year, as part of MPE’s work with IMI PREFER, MPE and KU Leuven presented findings from a study on patient preferences at the 2021 European Hematology Association congress. This study also resulted in a paper published in Frontiers in Medicine, with a future paper under review, which suggests that patients focus not only on treatment efficacy, but also value a reduction of myeloma-related symptoms and side effects. Furthermore, as a result of this study, the EMA is now looking more closely at how patient preference data can be more effectively incorporated into decision-making.

MPE continues its role as a work package leader in SISAQOL-IMI (Setting International Standards of Patient-Reported Outcomes and Quality of Life Endpoints in Cancer Clinical Trials – IMI). Currently in year two of the four-year research project, this year, MPE led the launch of the new SISAQOL-IMI website, communications strategy and social media campaign, facilitating meaningful dialogue between the patient community and consortium stakeholders to ensure that the results of this project are of true value for cancer patients in Europe. The discoveries made through SISAQOL-IMI will result in recommendations to standardise the use, analysis and interpretation of PRO data in cancer clinical trials in the future.

MPE continues its work on Horizon 2020 CARAMBA, a five-year research collaboration between 10 partners from six EU countries. This consortium is researching an innovative immunotherapy for the treatment of multiple myeloma, known as Chimeric Antigen Receptor T-cell therapy (CAR-T). Through strategic collaboration with a wide-range of stakeholders, the consortium aims to ensure the streamlined transition of a CAR-T product from the laboratory to myeloma patients in the clinic. In 2021, MPE developed CARAMBA pipeline and Q&A documents, published an educational video and Q&A on CAR-T for the patient
community, finalised a protocol for the research MPE will conduct as part of CARAMBA and initiated research projects on the patient perspective on the impact of CAR-T treatment and the use of Patient Reported Outcomes (PRO) in CAR-T clinical trials.

MPE is also a collaborator in IMI HARMONY, a project consortium involving over 50 partners from across the haematological community. HARMONY aims to facilitate the growth of personalised medicine and the identification of the most effective treatments, and improve diagnosis by collecting and disseminating valuable clinical data on hematologic malignancies through a big data platform. This year, MPE advocated for the inclusion of Patient Reported Outcomes and Quality of Life (QoL) data into the HARMONY platform and actively contacted data contributors to share or update their data with HARMONY. This PRO and QoL data will allow patient communities to submit research proposals linked with quality of life and study how treatments affect patients’ everyday lives. This data will also help detect barriers and areas to be improved to ensure quality of life and patient centricity in myeloma research. MPE also attended the HARMONY 6th general assembly in November 2021 to represent the myeloma patient community, bring the patient perspective on big data and make sure patients’ interests are kept central.

**SISAQOL**
Setting International Standards of Patient-Reported Outcomes and Quality of Life Endpoints in Cancer Clinical Trials

**IMI PREFER**
Patient preferences in myeloma treatment

**HARMONY**
Harmony aims to facilitate the growth of personalised medicine
MPE was born following the merger in 2011 of the European Myeloma Platform and Myeloma Euronet. The new organisation was registered as non-profit in Brussels, Belgium.

MPE launches its website, its main communication tool and primary method to engage and interact with stakeholders and the patient community.

MPE hires its first employee. Ananda Plate becomes CEO of the organisation.

MPE sets up a booth for the first time in the Patient Advocacy Area of the largest haematology event in the world: American Society of Hematology (ASH) Annual Meeting.

MPE, along with 14 other European cancer patient organisations, forms the Workgroup of European Cancer Advocacy Networks (WECAN) to facilitate collaborative cancer patient advocacy.

MPE launches the Myeloma Access Atlas, one of its most innovative programmes to date, and the current MPE president, Hans Scheurer, is elected at the AGM.

The MPE Advocate Development Programme (ADP) begins with a cohort of six participants.

The membership decides to include AL amyloidosis in the MPE work area. Since 2018, amyloidosis organisations have had the option to join MPE as full members.

MPE holds its first Myeloma Community Advisory Board (CAB). So far, MPE has held 13 CABs in two years.

COVID-19 pandemic hits the world and MPE holds its General Assembly virtually for the first time. All programmes and projects are adapted to the new reality.

MPE celebrates its 10th Anniversary with a staff of 15 people and 49 member organisations in 31 different countries.

A special thank you to our members who, once again, have shown their extraordinary commitment to supporting patients, carers and families across Europe, and have overcome enormous challenges during this difficult year.
MPE 2021 Funders

Pharmaceutical Industry Supporters:
- Amgen
- Bristol Myers Squibb
- GlaxoSmithKline
- Gilead
- Janssen
- Karyopharm
- Novartis
- Pfizer
- Roche
- Sanofi
- Takeda

Public Supporters:
- Horizon 2020 CARAMBA
- Horizon 2020 MMPREDICT
- IMI HARMONY
- SISAQOL IMI

Thank you!

MPE is very grateful for the continued support of our partners and would like to thank them for their generosity this year.

Get involved in MPE patient-focused activities and research

Click here to find out more
CONTACT US

Myeloma Patients Europe AISBL
Avenue Louise 143/4
1050 Brussels - Belgium

info@mpeurope.org
www.mpeurope.org
@mpeurope
@MyelomaEurope

Myeloma Patients Europe
Myeloma Patients Europe